CYTK Cytokinetics, Incorporated - Common Stock
$76.55
价格 · 八月 20, 2026
截至...的财报数据 八月 6, 2026
52周区间
$35–$88
78% of range
分析师评级
BUY
28 analysts
目标价
$110
+44% upside
P/E (TTM)
-11.7
ROE
152.7%
净利润率
-891.6%
关于 Cytokinetics, Incorporated - Common Stock 公司概况（来自维基百科）
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
阅读更多
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
CYTK 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$76.55
市值
$9.41B
P/E (TTM)
-11.7
每股收益 (TTM)
$-6.54
营收 (TTM)
$88M
股息收益率
—
ROE
152.7%
负债/权益
-0.4
52周区间
$35 – $88
CYTK 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$88M
2016-12-31
→
2025-12-31
EPS
$-6.54
2016-12-31
→
2025-12-31
自由现金流
$-535M
2016-12-31
→
2025-12-31
利润率
-891.6%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
CYTK
同行中位数
P/E (TTM)
-11.7
28.5
P/S (TTM) (市销率 (TTM))
106.9
20.1
P/B (市净率)
-14.3
12.9
EV / EBITDA (企业价值 / EBITDA)
-15.9
—
Price / FCF (股价/自由现金流)
-17.6
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
CYTK
同行中位数
Operating Margin (营业利润率)
-695.4%
—
Net Profit Margin (净利润率)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
CYTK
同行中位数
Debt / Equity (负债/股东权益比率)
-0.4
—
Current Ratio (流动比率)
4.5
5.0
Quick Ratio (速动比率)
0.7
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
CYTK
同行中位数
Revenue YoY (营收同比增长)
376.6%
—
Revenue CAGR 3Y (营收3年复合年增长率)
-2.4%
—
Revenue CAGR 5Y (营收5年复合年增长率)
9.5%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
CYTK
同行中位数
CYTK 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
28 位分析师
- 强烈买入 6 21.4%
- 买入 19 67.9%
- 持有 3 10.7%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
20 位分析师 · 2026-08-18
中位数
$107.50
← 低于所有目标
$76.55
最低
$85.00
最高
$146.00
中位数目标
$107.50
+40.4%
平均目标
$109.90
+43.6%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-0.08%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.50 | $-1.67 | 0.17% |
| 2026年3月31日 | $-1.67 | $-1.69 | 0.02% |
| 2025年12月31日 | $-1.50 | $-1.49 | -0.01% |
| 2025年9月30日 | $-2.55 | $-1.61 | -0.94% |
| 2025年6月30日 | $-1.12 | $-1.41 | 0.28% |
| 2025年3月31日 | $-1.39 | $-1.41 | 0.02% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
资产负债表 26
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
现金流 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
流动性与偿付能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
资产负债表 24
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
现金流 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
流动性与偿付能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
估值 (TTM) 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $88M | $18M | $8M | $95M | $70M |
| 营业利润率 % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| 净收入 | $-785M | $-590M | $-526M | $-389M | $-215M |
| 稀释后每股收益 (EPS) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| 流动比率 | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| 速动比率 | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-535M | $-400M | $-416M | $-311M | $-191M |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 540 家申报者 · $9.0B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 104 (0 与上一季度对比) | 49 (-6 与上一季度对比) | 222 (+43 与上一季度对比) | 112 (-32 与上一季度对比) | +5.3M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571778157 | 6711799 | 6.37% | 股份 |
| STATE STREET CORP | $553243709 | 6494233 | 6.16% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $521151103 | 6117515 | 5.80% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $509521049 | 5980996 | 5.67% | 股份 |
| Avoro Capital Advisors LLC | $425949915 | 4999999 | 4.74% | 股份 |
| FMR LLC | $375035430 | 4402341 | 4.18% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $259207450 | 3042018 | 2.89% | 股份 |
| BANK OF AMERICA CORP /DE/ | $251706463 | 2954648 | 2.80% | 股份 |
| RTW INVESTMENTS, LP | $243814036 | 2862003 | 2.72% | 股份 |
| Polar Capital Holdings Plc | $191988358 | 2253649 | 2.14% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161060214 | 1890600 | 1.79% | 买入期权 |
| Capital Research Global Investors | $143683584 | 1686625 | 1.60% | 股份 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136597224 | 1603442 | 1.52% | 股份 |
| Integral Health Asset Management, LLC | $136304000 | 1600000 | 1.52% | 股份 |
| Point72 Asset Management, L.P. | $135257185 | 1587712 | 1.51% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133386924 | 1565758 | 1.49% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131998327 | 1549458 | 1.47% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $111435932 | 1308087 | 1.24% | 股份 |
| Capital International Investors | $111245191 | 1305848 | 1.24% | 股份 |
| ARMISTICE CAPITAL, LLC | $106487500 | 1250000 | 1.19% | 买入期权 |
| ARMISTICE CAPITAL, LLC | $102342325 | 1201342 | 1.14% | 股份 |
| Pictet Asset Management Holding SA | $99038455 | 1160463 | 1.10% | 股份 |
| Frazier Life Sciences Management, L.P. | $98810092 | 1159879 | 1.10% | 股份 |
| Holocene Advisors, LP | $97506685 | 1144579 | 1.09% | 股份 |
| Woodline Partners LP | $93769315 | 1100708 | 1.04% | 股份 |
| NORGES BANK | $86512319 | 1015522 | 0.96% | 股份 |
| Royalty Pharma Sub-Manager, LLC | $83519594 | 980392 | 0.93% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81937000 | 961815 | 0.91% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $77218175 | 906423 | 0.86% | 股份 |
| CITADEL ADVISORS LLC | $77062874 | 904600 | 0.86% | 买入期权 |
| Melqart Asset Management (UK) Ltd | $65385455 | 767525 | 0.73% | 股份 |
| Siren, L.L.C. | $64655121 | 758952 | 0.72% | 股份 |
| Fisher Asset Management, LLC | $63355547 | 743697 | 0.71% | 股份 |
| Foresite Capital Management IV, LLC | $60884867 | 714695 | 0.68% | 股份 |
| Balyasny Asset Management L.P. | $60599821 | 711349 | 0.67% | 股份 |
| Deep Track Capital, LP | $59633000 | 700000 | 0.66% | 股份 |
| JANE STREET GROUP, LLC | $59633000 | 700000 | 0.66% | 买入期权 |
| BNP PARIBAS FINANCIAL MARKETS | $58702470 | 689077 | 0.65% | 股份 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56251809 | 660310 | 0.63% | 股份 |
| CITADEL ADVISORS LLC | $54601338 | 640936 | 0.61% | 股份 |
| GOLDMAN SACHS GROUP INC | $54053311 | 634503 | 0.60% | 股份 |
| Qube Research & Technologies Ltd | $48774257 | 572535 | 0.54% | 股份 |
| EVENTIDE ASSET MANAGEMENT, LLC | $48081832 | 564398 | 0.54% | 股份 |
| Affinity Asset Advisors, LLC | $46854500 | 550000 | 0.52% | 股份 |
| First Turn Management, LLC | $44930228 | 527412 | 0.50% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $44162525 | 518398 | 0.49% | 股份 |
| Caption Management, LLC | $43651356 | 512400 | 0.49% | 买入期权 |
| D. E. Shaw & Co., Inc. | $40874247 | 479801 | 0.46% | 股份 |
| Checkpoint Capital L.P. | $40465250 | 475000 | 0.45% | 股份 |
| Hood River Capital Management LLC | $39977367 | 469273 | 0.45% | 股份 |
| RP Management, LLC | $39401954 | 980392 | 0.44% | 股份 |
| EMERALD ADVISERS, LLC | $39013272 | 457956 | 0.43% | 股份 |
| ADAR1 Capital Management, LLC | $39009097 | 457907 | 0.43% | 股份 |
| AMERIPRISE FINANCIAL INC | $38010006 | 446179 | 0.42% | 股份 |
| Candriam S.C.A. | $37708477 | 443066 | 0.42% | 股份 |
| MARSHALL WACE, LLP | $36259335 | 425629 | 0.40% | 股份 |
| RHUMBLINE ADVISERS | $35933015 | 421799 | 0.40% | 股份 |
| CITADEL ADVISORS LLC | $35882028 | 421200 | 0.40% | 卖出期权 |
| ALLIANCEBERNSTEIN L.P. | $35327299 | 535993 | 0.39% | 股份 |
| GILDER GAGNON HOWE & CO LLC | $34096829 | 400245 | 0.38% | 股份 |
| TD Asset Management Inc | $32809225 | 385130 | 0.37% | 股份 |
| BlackRock, Inc. | $29124928 | 341882 | 0.32% | 股份 |
| GSK plc | $29001573 | 340434 | 0.32% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $27040243 | 317411 | 0.30% | 股份 |
| CITIGROUP INC | $26852314 | 315205 | 0.30% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24671024 | 289600 | 0.27% | 卖出期权 |
| Trails Edge Capital Partners, LP | $24542302 | 288089 | 0.27% | 股份 |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23833521 | 279769 | 0.27% | 股份 |
| Polaris Capital Management, LLC | $22737211 | 266900 | 0.25% | 股份 |
| SEGALL BRYANT & HAMILL, LLC | $21899197 | 257063 | 0.24% | 股份 |
| Alyeska Investment Group, L.P. | $21297500 | 250000 | 0.24% | 股份 |
| ExodusPoint Capital Management, LP | $21234374 | 249259 | 0.24% | 股份 |
| Capital World Investors | $21196550 | 248815 | 0.24% | 股份 |
| Walleye Capital LLC | $20422428 | 239728 | 0.23% | 股份 |
| E. Ohman J:or Asset Management AB | $19823223 | 300762 | 0.22% | 股份 |
| Sarissa Capital Management LP | $19476393 | 228623 | 0.22% | 股份 |
| Swiss National Bank | $18946256 | 222400 | 0.21% | 股份 |
| SPHERA FUNDS MANAGEMENT LTD. | $18740693 | 219987 | 0.21% | 股份 |
| BAKER BROS. ADVISORS LP | $17997836 | 211267 | 0.20% | 股份 |
| California Public Employees Retirement System | $17979520 | 211052 | 0.20% | 股份 |
| Nicholas Investment Partners, LP | $17810758 | 209071 | 0.20% | 股份 |
| PINNACLE ASSOCIATES LTD | $17245864 | 202440 | 0.19% | 股份 |
| Mirador Capital Partners LP | $17239900 | 202370 | 0.19% | 股份 |
| Tri Locum Partners LP | $16526860 | 194000 | 0.18% | 股份 |
| PFM Health Sciences, LP | $16329730 | 191686 | 0.18% | 股份 |
| Rock Springs Capital Management LP | $16014016 | 187980 | 0.18% | 股份 |
| PRUDENTIAL FINANCIAL INC | $15933512 | 187035 | 0.18% | 股份 |
| DAFNA Capital Management LLC | $14652510 | 171998 | 0.16% | 股份 |
| Ghisallo Capital Management LLC | $14482300 | 170000 | 0.16% | 股份 |
| Impax Asset Management Group plc | $14056350 | 165000 | 0.16% | 股份 |
| Lombard Odier Asset Management (Europe) Ltd | $13494096 | 158400 | 0.15% | 买入期权 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13383349 | 157100 | 0.15% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13330276 | 156477 | 0.15% | 股份 |
| JANE STREET GROUP, LLC | $12735905 | 149500 | 0.14% | 卖出期权 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12145719 | 139190 | 0.14% | 股份 |
| Retirement Systems of Alabama | $11962891 | 140426 | 0.13% | 股份 |
| MetLife Investment Management, LLC | $11930519 | 140046 | 0.13% | 股份 |
| Polymer Capital Management (HK) LTD | $11777943 | 138255 | 0.13% | 股份 |
| Cinctive Capital Management LP | $11742419 | 137838 | 0.13% | 股份 |
| TUDOR INVESTMENT CORP ET AL | $11279156 | 132400 | 0.13% | 买入期权 |
公司内部人士 52 位内幕人士 · 18 位高管 · 22 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 2026年7月1日 M | 63221 | 0 | 5 | $-5695855 |
| Ching Jaw | SVP Finance & CFO | 2023年3月6日 A | 87346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 2017年2月28日 F | 40323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 2026年8月18日 M | 153902 | 0 | 21 | $-4352750 |
| Andrew Callos | EVP, Chief Commercial Officer | 2026年7月30日 M | 58555 | 0 | 24 | $-15318893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 2026年3月15日 A | 107943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 2024年12月3日 A | 18655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 2024年8月30日 A | 33140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 2022年3月15日 M | 103408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 2022年3月7日 F | 153233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 2018年2月27日 A | 32548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 2018年2月27日 A | 21520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 2017年8月31日 M | 46441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 2017年2月28日 A | 29004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 2017年2月28日 A | 47255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 2011年2月28日 A | 42000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 2009年12月18日 M | 20043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 2008年2月29日 A | 47896 | 0 | 0 | $0 |
| Robert Arthur Harrington | 董事 | 2026年7月15日 A | 21932 | 0 | 2 | $-248260 |
| James M Daly | 董事 | 2026年7月15日 A | 3390 | 0 | 0 | $0 |
| Edward M. Kaye MD | 董事 | 2026年7月15日 A | 10434 | 0 | 6 | $-3544372 |
| Nancy Wysenski | 董事 | 2026年7月15日 A | 33992 | 0 | 0 | $0 |
| Wendell Wierenga | 董事 | 2026年7月15日 A | 35563 | 0 | 3 | $-1881925 |
| John T Henderson | 董事 | 2026年7月15日 A | 78360 | 0 | 2 | $-2078525 |
| Lynne B Parshall | 董事 | 2026年6月1日 S | 15784 | 0 | 3 | $-1000100 |
| Muna Bhanji | 董事 | 2026年5月27日 A | 26361 | 0 | 0 | $0 |
| Robert E Landry | 董事 | 2026年5月27日 A | 10184 | 0 | 0 | $0 |
| Wendall Wierenga | 董事 | 2025年7月15日 A | 32345 | 0 | 0 | $0 |
| COSTA SANTO J | 董事 | 2024年5月15日 A | 20600 | 0 | 0 | $0 |
| Sandford D Smith | 董事 | 2024年1月2日 A | 18801 | 0 | 0 | $0 |
| Robert Califf | 董事 | 2022年1月3日 A | 6003 | 0 | 0 | $0 |
| GAGE L PATRICK | 董事 | 2021年11月8日 M | 28932 | 0 | 0 | $0 |
| Denise Gilbert | 董事 | 2015年5月20日 J | — | 0 | 0 | $0 |
| Stephen M Dow | 董事 | 2013年1月2日 A | 1421052 | 0 | 0 | $0 |
| James A Spudich | 董事 | 2011年5月18日 A | 180600 | 0 | 0 | $0 |
| Grant A Heidrich III | 董事 | 2011年1月3日 A | 93755 | 0 | 0 | $0 |
| Michael Schmertzler | 董事 | 2010年6月3日 S | 4340923 | 0 | 0 | $0 |
| Mark Mcdade | 董事 | 2009年5月21日 A | — | 0 | 0 | $0 |
| Charles J Homcy | 董事 | 2008年5月22日 A | — | 0 | 0 | $0 |
| William J Rutter | 董事 | 2004年4月29日 C | 172413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10% 所有者 | 2004年4月29日 C | 1615716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10% 所有者 | 2004年4月29日 C | 771052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10% 所有者 | 2004年4月29日 C | 650000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10% 所有者 | 2004年4月29日 C | 755631 | 0 | 0 | $0 |
| Robert I Blum | — | 2026年8月10日 M | 377820 | 0 | 19 | $-9702097 |
| Elisabeth Schnieders | — | 2017年2月28日 A | 43919 | 0 | 0 | $0 |
| James H Sabry | — | 2010年6月3日 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 2004年4月29日 C | 24050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 2004年4月29日 C | 625950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 2004年4月29日 C | 1742951 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 84 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3.16% | 43268 NS | 2026年5月31日 | N-PORT |
| HRTS · Tema ETF Trust | 2.52% | 17069 NS | 2026年5月31日 | N-PORT |
| FMED · Fidelity Covington Trust | 1.55% | 8262 NS | 2026年5月31日 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1.40% | 3663 NS | 2026年5月31日 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1.24% | 189801 NS | 2026年4月30日 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.98% | 48338 NS | 2026年4月30日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.94% | 76297 NS | 2026年4月30日 | N-PORT |
| BBC · ETFis Series Trust I | 0.75% | 4355 NS | 2026年4月30日 | N-PORT |
| FNY · First Trust Exchange-Traded Alpha... | 0.51% | 41612 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.47% | 4553 NS | 2026年5月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.47% | 94565 NS | 2026年4月30日 | N-PORT |
| MIDE · DBX ETF Trust | 0.41% | 178 NS | 2026年5月29日 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.34% | 16959 NS | 2026年4月30日 | N-PORT |
| FNX · First Trust Exchange-Traded Alpha... | 0.26% | 55086 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.25% | 6062 NS | 2026年5月31日 | N-PORT |
| RSSL · Global X Funds | 0.23% | 51834 NS | 2026年4月30日 | N-PORT |
| PTMC · Pacer Funds Trust | 0.23% | 14028 NS | 2026年4月30日 | N-PORT |
| MVV · ProShares Trust | 0.22% | 4565 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.21% | 635330 NS | 2026年5月31日 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.20% | 19862 NS | 2026年4月30日 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0.19% | 356940 NS | 2026年5月31日 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0.19% | 37821 NS | 2026年4月30日 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.15% | 2025 NS | 2026年4月30日 | N-PORT |
| UMDD · ProShares Trust | 0.15% | 638 NS | 2026年5月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.15% | 11444 NS | 2026年4月30日 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund ... | 0.15% | 47609 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.15% | 4765 NS | 2026年5月31日 | N-PORT |
| SMDX · Tidal Trust III | 0.15% | 2868 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.12% | 53720 NS | 2026年4月30日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.12% | 154 NS | 2026年5月31日 | N-PORT |
| NBCR · Neuberger Berman ETF Trust | 0.10% | 12090 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.10% | 4793 NS | 2026年5月31日 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.06% | 2263 NS | 2026年5月31日 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.06% | 5490 NS | 2026年4月30日 | N-PORT |
| ESLV · Strategy Shares | 0.05% | 100 NS | 2026年4月30日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.05% | 4582 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 5851 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.04% | 121 NS | 2026年5月31日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.02% | 30621 NS | 2026年5月31日 | N-PORT |
| TILT · FlexShares Trust | 0.02% | 5462 NS | 2026年4月30日 | N-PORT |
| SCHK · SCHWAB STRATEGIC TRUST | 0.01% | 10669 NS | 2026年5月31日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.01% | 78165 NS | 2026年5月31日 | N-PORT |
| GUSA · Goldman Sachs ETF Trust II | 0.01% | 3973 NS | 2026年5月31日 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.01% | 570 NS | 2026年5月31日 | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0.01% | 1547 NS | 2026年5月31日 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.01% | 173 NS | 2026年5月31日 | N-PORT |
| FTLS · First Trust Exchange-Traded Fund III | -0.10% | -35935 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VB · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |